ATE339446T1 - Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität - Google Patents

Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität

Info

Publication number
ATE339446T1
ATE339446T1 AT02732448T AT02732448T ATE339446T1 AT E339446 T1 ATE339446 T1 AT E339446T1 AT 02732448 T AT02732448 T AT 02732448T AT 02732448 T AT02732448 T AT 02732448T AT E339446 T1 ATE339446 T1 AT E339446T1
Authority
AT
Austria
Prior art keywords
csf
stimulating factor
granulocyte macrophage
human granulocyte
modified human
Prior art date
Application number
AT02732448T
Other languages
English (en)
Inventor
Francis J Carr
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE339446T1 publication Critical patent/ATE339446T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02732448T 2001-03-08 2002-02-28 Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität ATE339446T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01105775 2001-03-08

Publications (1)

Publication Number Publication Date
ATE339446T1 true ATE339446T1 (de) 2006-10-15

Family

ID=8176721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02732448T ATE339446T1 (de) 2001-03-08 2002-02-28 Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität

Country Status (15)

Country Link
US (1) US7208147B2 (de)
EP (1) EP1366074B1 (de)
JP (1) JP2004535777A (de)
KR (1) KR20030082962A (de)
CN (1) CN1494551A (de)
AT (1) ATE339446T1 (de)
BR (1) BR0207945A (de)
CA (1) CA2439926A1 (de)
DE (1) DE60214682T2 (de)
HU (1) HUP0303429A3 (de)
MX (1) MXPA03008032A (de)
PL (1) PL362986A1 (de)
RU (1) RU2003129058A (de)
WO (1) WO2002070548A2 (de)
ZA (1) ZA200307829B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7741450B2 (en) 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF
AU2013201228B2 (en) * 2006-02-08 2016-01-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
CA2857539C (en) 2011-11-29 2021-08-03 Neurophage Pharmaceuticals, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
EP2968450A4 (de) 2013-03-15 2016-10-26 Angelica Therapeutics Inc Modifizierte toxine
AU2014274253B2 (en) 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
BR112017011530A2 (pt) 2014-12-03 2018-03-13 Proclara Biosciences Inc polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação
TW201808987A (zh) 2016-06-08 2018-03-16 健生生物科技公司 Gm-csf變體及使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
EP0983303B1 (de) * 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity

Also Published As

Publication number Publication date
EP1366074A2 (de) 2003-12-03
JP2004535777A (ja) 2004-12-02
KR20030082962A (ko) 2003-10-23
BR0207945A (pt) 2004-07-27
EP1366074B1 (de) 2006-09-13
US20040092717A1 (en) 2004-05-13
DE60214682T2 (de) 2007-09-13
HUP0303429A2 (hu) 2004-01-28
WO2002070548A2 (en) 2002-09-12
CA2439926A1 (en) 2002-09-12
MXPA03008032A (es) 2003-12-04
PL362986A1 (en) 2004-11-15
WO2002070548A3 (en) 2003-05-01
US7208147B2 (en) 2007-04-24
HUP0303429A3 (en) 2005-12-28
CN1494551A (zh) 2004-05-05
ZA200307829B (en) 2004-07-21
RU2003129058A (ru) 2005-04-20
DE60214682D1 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
WO2002074783A3 (en) Modified interferon beta with reduced immunogenicity
WO2002062832A3 (en) Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
ATE339446T1 (de) Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität
WO2002062843A3 (en) Modified erythropoietin (epo) with reduced immunogenicity
AU2210899A (en) Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
MXPA03010649A (es) Administracion pulmonar de insulina modificada quimicamente.
EA200100939A1 (ru) Продолжительно действующие инсулинотропные пептиды
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
MY129566A (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
WO2003040398A3 (en) Proteins stabilized with polysaccharide gums
WO2006010143A3 (en) Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2002085941A3 (en) Modified interferon alpha with reduced immunogenicity
GB2255093A (en) Hiv-1 core protein fragments
WO2002062833A3 (en) Modified leptin with reduced immunogenicity
BR0207014A (pt) Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida.
WO2002077034A3 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
ATE515258T1 (de) Mukosales verabreichungssytem
HUP0303310A2 (hu) Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF)
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
MXPA04000339A (es) MeTODOS PARA REDUCIR INMUNOGENICIDAD DE POLIPePTIDOS.
DK1173476T3 (da) Funktionelle sojabönneproteiner
BR0207905A (pt) Protamina modificada com imunogenicidade reduzida
WO2002068469A3 (en) Modified thrombopoietin with reduced immunogenicity
WO2002074808A3 (en) Modified insulin with reduced immunogenicity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties